Elutia Inc. Stock Price, News & Analysis

Elutia (Nasdaq: ELUT) has received dual honors at the 2025 Medical Device Network Excellence Awards for Innovation and Product Launches, recognizing their EluPro™ Antibiotic-Eluting BioEnvelope technology. EluPro, launched in January 2025, is designed to protect cardiac implantable electronic devices and neurostimulators.

The product has shown strong commercial performance with 84% sequential sales growth in Q1 2025 and drove a 31% year-over-year increase in BioEnvelope sales. EluPro has secured approvals from 150 hospital value analysis committees and partnerships with seven major group purchasing organizations.

The technology addresses a significant market need, with over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases.

Elutia (NASDAQ: ELUT) has published a groundbreaking peer-reviewed article in Dissolution Technologies, introducing a validated method for measuring antibiotic release from biologic envelopes. The innovative testing approach delivers results in just 30 hours compared to traditional 14-day in vivo protocols, significantly accelerating product development while reducing costs. The method specifically supports EluPro™, the company's FDA-cleared antibiotic-eluting bioenvelope designed for cardiac implantable electronic devices and neurostimulators, which was launched in January 2025. The testing protocol effectively captures the biphasic release profile of minocycline and rifampin, measuring both immediate and sustained release phases. This advancement strengthens Elutia's drug-eluting biomatrix platform and facilitates faster development of future products in their pipeline.

Elutia (NASDAQ: ELUT) reported strong Q1 2025 results, highlighted by an 84% sequential growth in EluPro™ sales. The company's BioEnvelope revenue grew 31% year-over-year to $3.1 million, with EluPro accounting for 52% of BioEnvelope sales. Overall net sales decreased 10% to $6.0 million. Key developments include a new strategic partnership with Boston Scientific to accelerate EluPro adoption, with a combined sales force of over 900 professionals. The company secured over 125 value analysis committee approvals and signed two new GPO contracts. Elutia strengthened its financial position by raising $15.0 million through a registered direct offering and amending loan terms. The company's gross margin was 40.7%, and adjusted EBITDA showed a loss of $3.3 million. Cash balance as of March 31, 2025, stood at $17.4 million.

Elutia (NASDAQ: ELUT) announced the transition to direct distribution of its cardiovascular product portfolio, ending its distribution agreement with LeMaitre Vascular. The company has appointed Dwayne Montgomery as Head of Cardiovascular and recruited 26 independent sales representatives dedicated to the cardiovascular line.

The cardiovascular portfolio, which includes ProxiCor®, VasCure®, and Tyke®, generated $2.9 million in revenue (12% of total) in 2024 and is expected to achieve 80% gross margins. These regenerative biomatrix products are designed for various cardiac and vascular repairs, offering advantages over synthetic alternatives by promoting healthy immune responses.

The strategic move aims to enhance top-line growth, improve gross margins and profitability, and provide greater strategic control over sales operations.

Elutia (Nasdaq: ELUT), a company specializing in drug-eluting biomatrix technologies, has scheduled the release of its Q1 2025 financial results for Thursday, May 8, 2025, after market close. The management team will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. U.S. investors can join via 877-407-8029, while international investors can dial 201-689-8029 using Conference ID 13753035. A live and archived webcast will be available on the company's investor relations website.

Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix technologies, has announced its participation in Chardan's Trending Issues in Drug Development Conference Series. The company's Chief Scientific Officer, Dr. Michelle LeRoux Williams, will join a fireside chat discussion focused on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape' on Tuesday, April 29, 2025, at 11:00 a.m. ET.

The virtual event will be accessible to investors and interested parties through a live webcast, with an archived version available afterward on the company's investor relations website at investors.elutia.com.

Elutia (NASDAQ: ELUT) has launched a real-world clinical study for EluPro™, their FDA-cleared antibiotic-eluting bioenvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators. The first patient enrollment occurred at UC San Diego Health.

The prospective, post-market study aims to evaluate EluPro's performance in standard clinical practice across diverse CIED implantation patients. The study will track 100 patients for 12 months, monitoring complications like infection, hematoma, lead dislodgement, and device migration.

EluPro combines rifampin and minocycline antibiotics with a regenerative biomatrix, addressing the U.S. market where over 600,000 CIEDs are implanted annually with 5-7% complication rates. The CIED protection market is valued at $600 million in the U.S.

Elutia (Nasdaq: ELUT) has announced that global tariffs have not materially impacted its operations or commercial performance. The company's business model, centered on 100% U.S.-based sourcing, manufacturing, and distribution, primarily through its Roswell, Georgia facility, has effectively insulated it from international trade uncertainties.

The company's product portfolio, including EluPro™, CanGaroo®, SimpliDerm®, and its Cardiovascular line, is entirely produced and sold within the United States. The FDA-registered Roswell facility has maintained normal operations without experiencing tariff-related delays, cost increases, or supplier issues. Elutia reports that its pricing and margins remain unaffected by the current global tariff environment.

Elutia (Nasdaq: ELUT) has received a 2025 Bronze Edison Award for their groundbreaking product EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope. The innovation was recognized in the Post-Surgical Recovery Solutions category.

Launched in January 2025, EluPro combines a regenerative biomatrix with rifampin and minocycline antibiotics, designed to protect patients with cardiac implanted electronic devices (CIEDs) and neurostimulation devices. The technology addresses critical needs in the medical device industry, where approximately 600,000 CIEDs are implanted annually in the U.S., with complications occurring in 5-7% of cases.

The award selection process involved rigorous evaluation by the Edison Awards Steering Committee and independent experts, considering concept, value, delivery, and impact. The award ceremony took place on April 3, 2025, at the Luminary Hotel and Caloosa Sound Convention Center in Fort Myers, Florida.